Study aim: Determining the effect of migrafar on migraine pain in children treated with emitriptyline Design: The clinical trial has a control group, one blind, randomly divided on 25 patients, randomly divided from A and B cards for randomization. First, it is numbered on paper according to the size of the sample from 1 to 50. Then two groups are randomly created with random elicitation software equal to the sample size and the generated numbers are placed in two study groups. Then, each person entering the study will take a card from the box and depending on the selected card, will be placed in the specified pawn. Settings and conduct: Outpatients referred to Imam Ali (AS) Shahrekord Clinic, who were visited by the children's neurology department in 1400-1401 and diagnosed with mild to moderate migraine, are studied in order to evaluate the effect of Migrafar capsules. Participants/Inclusion and exclusion criteria: Definitive diagnosis of migraine headache Mild to moderate headache intensity Not taking any other medicine for headache Intervention groups: Intervention group: recipient of standard drug Amirtriptyline along with Migrafar capsule Control group: recipient of the standard drug Amirtriptyline along with placebo (which is prepared and provided by Nutekfar pharmaceutical company) Main outcome variables: The amount of headache-quality of sleep